Drugs / Quadri Meningo
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT03263403 Comparator | Aug 2017 → Mar 2018 | meningococcal infection | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadri Meningo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03263403 ↗ |
| Known as | Quadri MeningoTM | “with Quadri MeningoTM (comparator), an approved meningococcal polysaccharide vaccine in India.” PMID 38897895 ↗ Jun 2024 |
| Modality | Vaccine | “Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited.” NCT03263403 ↗ |
| Route | Subcutaneous | “receiving a single dose vaccine subcutaneously” PMID 38897895 ↗ Jun 2024 |